Conigen Biosciences

Executive Summary

Conigen Biosciences is a San Diego-based life science tools company specializing in the engineering of bioactive recombinant proteins and precision antibody discovery services. Founded in 2017, the company focuses on producing soluble and membrane-associated proteins that retain native conformational epitopes, enabling more accurate antibody screening and drug discovery against challenging therapeutic targets such as GPCRs and ion channels. Conigen's proprietary platforms are designed to improve assay sensitivity and facilitate the development of antibodies for targets that are notoriously difficult to work with due to their structural complexity. The company's technology is positioned to accelerate preclinical research and fill a critical gap in the toolkit for translating novel biologics. As a private entity with no disclosed financing or revenue information, Conigen operates in a competitive landscape alongside other antibody discovery and protein engineering firms. Its success hinges on forming strategic partnerships with biopharma companies seeking differentiated reagents for hard-to-drug targets. While the company has not yet achieved significant commercial visibility, its specialized focus on conformational integrity in protein reagents offers a clear value proposition for partners engaged in complex target biology.

Upcoming Catalysts (preview)

• Q4 2026Announcement of major partnership with pharmaceutical company for GPCR-targeted antibody discovery services40% success
• Q2 2027Launch of new proprietary protein reagent line for ion channel targets50% success
• Q3 2026Disclosure of Series A financing round to scale operations and platform development35% success